Comparison of effects of two different analgesia methods in ultra-fast track cardiac anesthesia in children with congenital heart disease: dexmedetomidine versus paraspinal nerve block

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000030299

Enrollment

Unknown

Registered

2020-02-27

Start date

2019-10-08

Completion date

Unknown

Last updated

2020-03-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

congenital heart disease

Interventions

Group 1:Dexmedetomidine IV

Group 2:Ropivacaine paravertebral nerve block

control group:normal saline IV

Eligibility

Sex/Gender

All

Age

No minimum to 16 Years

Inclusion criteria

Inclusion criteria: 1. Born at full term with an age greater than one month; 2. The body weight is more than 3.5kg; 3. ASA i-iii level;Surgical risk rating for congenital heart disease: RACHS 1-3; 4. Satisfactory surgical orthopedics (TEE assessment). 5. The score of positive inotropic drugs less than 15 points

Exclusion criteria

Exclusion criteria: 1. Premature and newborn; 2. Weight less than 3.5kg; 4. Children undergoing emergency surgery and secondary heart surgery; 5. Severe preoperative pneumonia; 6. Severe liver and kidney dysfunction; 7. Severe central nervous system diseases; 8. Atrioventricular block.

Design outcomes

Primary

Measure	Time frame
sufentanil dose;exbutation time;	—

Secondary

Measure	Time frame
vital signs;hospital stay;hospital cost;demographic data;operation related index;Analgesic and sedation score;	—

Countries

China

Contacts

Public ContactJumian Feng

Guangzhou Women and Children's Medical Center

fjm618@foxmail.com+86 20 38076243

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026